All News

Your daily dose of the clinical news you may have missed.

Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.

ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.

The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.

Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.

Your daily dose of the clinical news you may have missed.

The 2 phase 3 trials met all primary and secondary endpoints, showing statistically significant reduction in symptoms and sleep disturbance and improvement in quality of life.

In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.

Your daily dose of the clinical news you may have missed.

Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.

New research shows that menstrual irregularity is associated with a higher prevalence of cardiometabolic conditions in women, even in the absence of PCOS.

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Your daily dose of the clinical news you may have missed.

Find details on a novel web tool found to help patients determine their eligibility for OTC statin use, FDA clearance of the first AI-based algorithm to detect HF during routine exams, and more.

DDW 24. Among patients aged 15 to 19 years, the incidence of CRC rose 333% over a 22-year period, researchers reported.

Your daily dose of the clinical news you may have missed.

While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.